Since Trius is waiting until the next release of data before partnering with anyone, I believe that Bayer will buy this company before that happens (so before the end of Q1). If you're Bayer, why would you wait for the release of more favorable data? Already being a partner in Asia, Bayer probably has their own data and can come to conclusions before the release of second p3.
That's an interesting thought..... and management seems in no hurry to partner in other territories, so maybe something is being worked out with Bayer? However, usually in most partnerships, the company seeking the partner makes a provision in the arrangement that the partnering company is not allowed to do a buyout unless there are other bidding companies. I'm not sure if this is the case with Trius' arrangement with Bayer? Maybe someone else can shine some light on this?